38090026|t|The Effect of Dezocine on the Median Effective Dose of Sufentanil-Induced Respiratory Depression in Patients Undergoing Spinal Anesthesia Combined with Low-Dose Dexmedetomidine.
38090026|a|Purpose: The application of sedation and analgesia in spinal anesthesia has many benefits, but the risk of respiratory depression (RD) caused by opioids cannot be ignored. We aimed to observe the effect of dezocine, a partial agonist of mu-receptor, on the median effective dose (ED50) of sufentanil-induced RD in patients undergoing spinal anesthesia combined with low-dose dexmedetomidine. Patients and Methods: Sixty-two patients were randomly assigned to dezocine group (DS) and control group (MS). After spinal anesthesia, mask oxygen (5 L/min) and dexmedetomidine (0.1 ug/kg) were given. Five minutes later, patients in the DS group received an Intravenous (IV) bolus of sufentanil and 0.05mg/kg dezocine, while patients in the MS group only received an IV bolus of sufentanil. Results: ED50 of DS group was 0.342 ug/kg, 95% confidence interval (CI) was (0.269, 0.623) ug/kg, and the ED50 of MS group was 0.291 ug/kg, 95% CI was (0.257, 0.346) ug/kg. There was no difference in the type and treatment measures of RD and hemodynamic changes between the two groups, and no serious adverse reactions occurred in either group. Conclusion: Dezocine can improve RD induced by sufentanil in patients with spinal anesthesia combined with low-dose dexmedetomidine, and increase the safety window of sufentanil use.
38090026	14	22	Dezocine	Chemical	MESH:C010827
38090026	55	65	Sufentanil	Chemical	MESH:D017409
38090026	74	96	Respiratory Depression	Disease	MESH:D012131
38090026	100	108	Patients	Species	9606
38090026	161	176	Dexmedetomidine	Chemical	MESH:D020927
38090026	285	307	respiratory depression	Disease	MESH:D012131
38090026	309	311	RD	Disease	MESH:D012131
38090026	384	392	dezocine	Chemical	MESH:C010827
38090026	467	477	sufentanil	Chemical	MESH:D017409
38090026	486	488	RD	Disease	MESH:D012131
38090026	492	500	patients	Species	9606
38090026	553	568	dexmedetomidine	Chemical	MESH:D020927
38090026	570	578	Patients	Species	9606
38090026	602	610	patients	Species	9606
38090026	637	645	dezocine	Chemical	MESH:C010827
38090026	653	655	DS	Chemical	MESH:D003903
38090026	676	678	MS	Disease	MESH:D009103
38090026	711	717	oxygen	Chemical	MESH:D010100
38090026	732	747	dexmedetomidine	Chemical	MESH:D020927
38090026	792	800	patients	Species	9606
38090026	808	810	DS	Disease	
38090026	855	865	sufentanil	Chemical	MESH:D017409
38090026	880	888	dezocine	Chemical	MESH:C010827
38090026	896	904	patients	Species	9606
38090026	912	914	MS	Disease	MESH:D009103
38090026	950	960	sufentanil	Chemical	MESH:D017409
38090026	979	981	DS	Chemical	MESH:D003903
38090026	1197	1199	RD	Disease	MESH:D012131
38090026	1319	1327	Dezocine	Chemical	MESH:C010827
38090026	1340	1342	RD	Disease	MESH:D012131
38090026	1354	1364	sufentanil	Chemical	MESH:D017409
38090026	1368	1376	patients	Species	9606
38090026	1423	1438	dexmedetomidine	Chemical	MESH:D020927
38090026	1474	1484	sufentanil	Chemical	MESH:D017409
38090026	Positive_Correlation	MESH:D017409	MESH:D012131
38090026	Positive_Correlation	MESH:D020927	MESH:D012131
38090026	Negative_Correlation	MESH:C010827	MESH:D017409
38090026	Negative_Correlation	MESH:C010827	MESH:D020927
38090026	Cotreatment	MESH:D017409	MESH:D020927
38090026	Negative_Correlation	MESH:C010827	MESH:D012131

